Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease

E. Coart, L.G. Barrado, F.H. Duits, P. Scheltens, W.M. van der Flier, C.E. Teunissen, S.M. van der Vies, T. Burzykowski

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)


Background: Studies investigating the diagnostic accuracy of biomarkers for Alzheimer's disease (AD) are typically performed using the clinical diagnosis or amyloid-β positron emission tomography as the reference test. However, neither can be considered a gold standard or a perfect reference test for AD. Not accounting for errors in the reference test is known to cause bias in the diagnostic accuracy of biomarkers. Objective: To determine the diagnostic accuracy of AD biomarkers while taking the imperfectness of the reference test into account. Methods: To determine the diagnostic accuracy ofADbiomarkers and taking the imperfectness of the reference test into account, we have developed a Bayesian method. This method establishes the biomarkers' true value in predicting the AD-pathology status by combining the reference test and the biomarker data with available information on the reliability of the reference test. The new methodology was applied to two clinical datasets to establish the joint accuracy of three cerebrospinal fluid biomarkers (amyloid-β
Original languageEnglish
Pages (from-to)889-899
JournalJournal of Alzheimer's Disease
Issue number4
Publication statusPublished - 2015

Cite this